A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.

Blood Cancer J · 2023 · PMC9834310 · PMID 36631458

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

Nonetheless, despite these limitations and the more conservative approach taken towards defining del(17p) positive patients, there was an overall trend in favor of ixazomib- vs placebo-based therapy.

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.